Retrospective analysis shows Black patients have shorter survival in acute myeloid leukemia, indicating disparities in genomic alterations and treatment outcomes.
Key Points
Black patients diagnosed with acute myeloid leukemia exhibited shorter overall survival compared to White and Hispanic cohorts, especially in the intermediate-risk group.
Median overall survival was 2.2 years for the entire cohort, with significant variation noted across racial groups during analysis.
Observational analysis at Moffitt Cancer Center assessed outcomes in over 620 patients diagnosed with acute myeloid leukemia from 2014 to 2024.
Disparities in genomic alterations among racial groups underscore the importance of increased minority representation in clinical trials.